Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T12:45:24.378Z.
Calculation as of: 2026-10-06T12:45:24.378Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 236ecad6846b0cc00793ea2ceb9f38c60eee5e96b58175726d9ae7432cdeb63e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$675.41M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$709.33M
EV/EBITDA Ratio
2.84x
TTM Avg
4.78x
3Y Avg
5.46x
5Y Avg
7.57x
Market Cap
$719.64M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$642.31M
EV/EBITDA Ratio
N/A
TTM Avg
8.45x
3Y Avg
304.75x
5Y Avg
435.98x
Market Cap
$734.10M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Annexon, Inc. (ANNX) | $688.14M | N/A | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $675.41M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $707.86M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 2.84x | 4.78x | 5.46x | 7.57x |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | N/A | N/A | N/A | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | N/A | 8.45x | 304.75x | 435.98x |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | N/A | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | N/A | 2.62x | 44.68x | 68.34x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
